The Tigecycline In Vitro Surveillance in Taiwan (TIST) Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC 90 , 0.03 g/ ml), and only one MRSA isolate (MIC 90 , 0.5 g/ml) and three VRE isolates (MIC 90 , 0.125 g/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC 90 , 0.5 g/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC 90 , 2 g/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate for A. baumannii (MIC 90 , 4 g/ml) decreased from 80.9% in 2006 to 55.3% in 2009 but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.
M
icrobial resistance is a major public health issue worldwide but especially in Asia (5, 11, 12) . It has a direct impact on mortality, morbidity, length of hospital stay, and health care costs (7) . Multidrug resistance has been found among many pathogens, including Gram-positive and Gram-negative bacteria. Among the most clinically relevant Gram-positive pathogens, methicillinresistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant enterococci (VRE) are the most common threats (1, 13) . Among the most clinically relevant Gram-negative bacteria, extendedspectrum ␤-lactamase (ESBL)-producing Enterobacteriaceae (such as Escherichia coli and Klebsiella pneumoniae), multidrugresistant Acinetobacter baumannii, and Stenotrophomonas malto-philia pose the greatest threats to health care systems (1, 4, 18) . These infections pose a great challenge to clinicians in regard to the choice of appropriate antimicrobial therapy, especially the initial empirical treatment. Continuous surveillance of antimicrobial susceptibility would provide important information locally and globally.
Tigecycline, the first semisynthetic glycylcycline available for clinical application, is a novel 9-t-butyl-substituted minocycline derivative that overcomes several major tetracycline resistance mechanisms (3). It demonstrates broad-spectrum antimicrobial effects against multiple resistant Gram-positive, Gram-negative, anaerobic, and atypical pathogens (3) . Tigecycline demonstrated excellent sustained in vitro activity against a wide spectrum of contemporary Gram-positive and Gram-negative pathogens from countries in the Asia-Pacific region in 2008 (10) . Tigecycline has been approved as the agent of choice for treating complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired lower respiratory tract infections (3).
The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, a nationwide, multicenter prospective surveillance study, was conducted by 20 medical centers and regional hospitals throughout Taiwan over a 5-year period (2006 to 2010) (10) . This program was initiated to monitor the tigecycline susceptibilities of several major clinically relevant antibiotic-resistant isolates of bacteria in hospitals in Taiwan.
MATERIALS AND METHODS
Bacterial isolates. During the period from 1 January 2006 to 31 December 2010, clinical isolates of MRSA (n ϭ 1,834), PRSP (n ϭ 423), VRE (n ϭ 219), ESBL-producing E. coli (n ϭ 1,141), ESBL-producing K. pneumoniae (n ϭ 1,330), A. baumannii (n ϭ 1,645), and S. maltophilia (n ϭ 903) were collected from different specimens at different hospitals ( Table  1 ). The isolates were identified as clinically relevant causative pathogens, and duplicate isolates from the same patients were excluded. These isolates were identified at each hospital and reconfirmed by the central laboratory at the National Taiwan University Hospital. Before testing, these isolates were stored at Ϫ70°C in Trypticase soy broth (BBL Microbiology Systems, Cockeysville, MD) supplemented with 15% glycerol.
Antimicrobial susceptibility testing. MICs of tigecycline were determined by the broth microdilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) (range, 0.008 to 16 g/ml) (6). The U.S. Food and Drug Administration (FDA) and European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011; www.eucast.org) criteria were used to interpret the results (Table 2) . Quality control tests were performed using S. pneumoniae ATCC 49619, S. aureus ATCC 25923, S. aureus ATCC 29213, E. faecalis ATCC 29212, E.
coli ATCC 25922 and 35218, and Pseudomonas aeruginosa ATCC 27853. Information about the susceptibility of A. baumannii isolates to carbapenems (either imipenem or meropenem), determined by the routine disk diffusion method, was available only for 2008 to 2010. There were no tigecycline breakpoints for A. baumannii recommended by the FDA and EUCAST. In this study, the tigecycline MIC interpretive breakpoints for Enterobacteriaceae recommended by the FDA (susceptible, Յ2 g/ml; intermediate, 4 g/ml; and resistant, Ն8 g/ml) were applied to Acinetobacter spp. (18) .
Statistical analysis. Linear regression analysis was used to analyze the trend in the rates of susceptibility of the tested organisms to tigecycline. A P value of Յ0.05 was considered statistically significant.
RESULTS
All PRSP isolates (100%; 423 isolates) were susceptible to tigecycline (Table 3 ). In addition, only one of the 1,834 isolates of MRSA and three of the 219 VRE isolates were nonsusceptible to tigecycline. Among the ESBL-producing Enterobacteriaceae species, 99.7% of ESBL-producing E. coli and 96.3% of ESBL-producing K. pneumoniae isolates were susceptible to tigecycline according to the FDA criteria. However, the susceptibility rates were 98.7% for ESBL-producing E. coli and 85.8% for ESBL-producing K. pneumoniae when EUCAST-2011 criteria were used. In addition, the susceptibility rate for A. baumannii was 68.2% according to the breakpoint criteria provided by the FDA and 35% according to criteria provided by EUCAST-2011.
Annual tigecycline susceptibility changes for each pathogen are shown in Table 4 . The only nonsusceptible MRSA isolate was found in 2007. The three nonsusceptible VRE isolates were iso- (Fig. 1A) . The MIC 50 and MIC 90 values were 2 and 4 g/ml, respectively, for S. maltophilia. There was a shift to higher MIC values during the period from 2006 to 2009, but a shift to lower MIC values was found during the period from 2009 to 2010 (Fig. 1B) .
The rate of susceptibility of A. baumannii to tigecycline varied in different hospitals and with the year (Fig. 2) . The susceptibility rates were higher in 2010 than in 2009 in 12 hospitals (H02, H03, H04, H05, H07, H10, H11, H12, H16, H18, H19, and H20).
The MIC distributions for A. baumannii isolates collected during 2008 to 2010 are shown in Fig. 3 . Among carbapenemnonsusceptible isolates, a unimodal distribution was found, with a peak at 2 to 4 g/ml (Fig. 3A) , and the rate of susceptibility to tigecycline was 48.9%. Among carbapenem-susceptible isolates, a bimodal MIC distribution with peaks at 0.25 and 2 to 4 g/ml was found (Fig. 3B) , and the rate of susceptibility to tigecycline was 69%. (19) . In addition, the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), a global surveillance study, showed that 99.98% of MRSA isolates (n ϭ 8,249) were susceptible to tigecycline (MIC 90 , 0.25 g/ml) during 2004 to 2009 (9) . In Canada, a prospective nationwide surveillance study (CANWARD 2008) showed that all MRSA isolates (n ϭ 272) were susceptible to tigecycline (21) .
In this study, the MIC 90 for VRE was low (0.125 g/ml) and was similar to the MIC 90 for VRE reported in the global T.E.S.T. study. In that study, both vancomycin-sensitive and vancomycinresistant E. faecalis (8, 576 and 201 isolates, respectively) showed the same MIC 90 values (0.25 g/ml). The present study also showed that all PRSP isolates were susceptible to tigecycline. However, the global T.E.S.T. study (2004 to 2008) revealed that 86.3% of PRSP isolates in Europe, 87% in Latin America, and 91.2% isolates in North America were susceptible to tigecycline (8) . Another global study (2004 to 2009) showed that 87.2% of penicillin-susceptible S. pneumoniae isolates (9,019 isolates), 91.8% of penicillin-intermediate S. pneumoniae isolates (510 isolates), and 91% of penicillin-resistant S. pneumoniae isolates (89 isolates) were susceptible to tigecycline (9) .
Among ESBL-producing Enterobacteriaceae, tigecycline still showed potent in vitro activity in our study. The susceptibility rate for ESBL-producing E. coli was more than 98% (99.6% by FDA criteria and 98.7% by EUCAST-2011 criteria). The susceptibility rate for ESBL-producing E. coli was higher than that for ESBLproducing K. pneumoniae, especially when measured using EUCAST-2011 breakpoint criteria. Similarly, in Mexico, 100% of ESBL-producing E. coli isolates and 94% of ESBL-producing K. pneumoniae isolates were susceptible to tigecycline during the period from 2005 to 2009, using the FDA interpretive criteria (19) . Furthermore, a multicenter study conducted during the period from 2004 to 2007 in countries of the Asia-Pacific Rim region showed that 100% of ESBL-producing E. coli isolates (MIC 90 , 0.5 g/ml) and 93.7% of ESBL-producing K. pneumoniae isolates (MIC 90 , 2 g/ml) were susceptible to tigecycline by the FDA interpretive criteria (2) . Although carbapenems are recommended for treating infections due to these ESBL-producing bacteria, tigecycline has been shown to be an alternative choice in the treatment of these infections according to data from the above-mentioned surveillance studies.
Data from the Asia-Pacific region in 2008 demonstrated a high rate of susceptibility (99.8%) to tigecycline among Acinetobacter spp., with an MIC 90 of 2 g/ml (10). The global T.E.S.T. study reported that A. baumannii isolates from blood cultures showed significant increases in tigecycline geometric mean MIC values in Europe (from 0.24 g/ml in 2004 to 0.34 g/ml in 2007; P ϭ 0.02) and in countries in the Asia-Pacific Rim region (from 0.16 g/ml in 2004 to 0.40 g/ml in 2007; P ϭ 0.02) but not in countries in North and South America (20) . In addition, the T.E.S.T study also reported that the rates of resistance of isolates from intensive care unit (ICU) patients were higher than those of isolates from non-ICU patients (20) .
In our study we found that the MIC distributions of A. baumannii differed among carbapenem-susceptible and carbapenem-nonsusceptible groups. In previous studies, different modes of MIC distribution were also found in different populations; however, those studies did not further analyze the difference according to the susceptibility of carbapenem (14, 20) . A bimodal distribution of tigecycline MICs for Acinetobacter spp. was found in North America, with clear peaks at 0.12 g/ml and 0.5 to 1 g/ml (14) , but a unimodal distribution was found in the European and Asia-Pacific Rim regions, both with a peak at 0.25 g/ml (20) .
Our study also addressed the differences in susceptibility rates obtained using FDA breakpoints and those obtained using EUCAST breakpoints. We found that the tigecycline susceptibility rates for ESBL-producing K. pneumoniae measured using FDA criteria were about 10% higher than those measured using EUCAST breakpoints. Similar differences in susceptibility rates obtained using the two criteria were noted in a study conducted in Greece, namely, that the susceptibility rates for K. pneumoniae were 99% according to FDA criteria and 91% as measured using EUCAST criteria (16) . That study also reported a major difference in susceptibility of isolates of Enterobacter spp. (16) . In a study conducted during the period from 2005 to 2009 in the United States, the rates of tigecycline susceptibility as measured by FDA and EUCAST criteria differed by 0.6% for ESBL-producing E. coli (100% versus 99.4%; n ϭ 334; P ϭ 0.499) and by 7.3% for K. pneumoniae (97.9% versus 90.6%; n ϭ 426; P Ͻ 0.001) (18) .
In our study, we found that the susceptibility rates determined by the two criteria for A. baumannii differed by about 30%. Certain resistance mechanisms (such as the overexpression of marA or ramA) in several Enterobacteriaceae species contribute to their increasing resistance to tigecycline (15, 17) . These mechanisms might contribute to this difference among A. baumannii isolates; proof of this requires further investigation. Further studies to investigate the correlation between in vitro results and clinical outcomes for patients with various infections due to these isolates are warranted.
In conclusion, continuous surveillance provides invaluable information for local or global health care specialists. Our data reveal that tigecycline continued to have potent antimicrobial effects against most Gram-positive and Gram-negative bacteria, namely, MRSA, VRE, PRSP, and ESBL-producing E. coli, during the period from 2006 to 2010 in Taiwan.
